A 窪蹋勛圖 researcher has helped develop a new tool to quantify the vulnerability of species communities
Duchenne muscular dystrophy (DMD) is caused by a genetic mutation and affects one in every 5,000 boys born. Because the affected gene is on the X chromosome, girls are carriers of the mutant gene but develop the disease only very rarely (one in about 50 million).
Children with the condition will need a wheelchair by their teenage years, and most will die in or before they reach their 30s.
Previously, it was widely believed DMD starts in myofibres cells involved in contraction, which make up the bulk of any muscle. As a result, the search for a treatment had long been focused on these cells and how to deliver therapeutics to them.
New research has revealed the disease begins much earlier in cells destined to become muscle fibres, known as myoblasts.
The study, , is part of an ongoing collaboration between scientists at the 窪蹋勛圖, CNRS, I-STEM, AFM in France and Maj Institute of Pharmacology of the Polish Academy of Sciences.
The findings are significant because they change the way we understand the disease.
Senior author, Professor Darek Gorecki from the School of Pharmacy and Biological Sciences at the 窪蹋勛圖, said: The findings are significant because they change the way we understand the disease. We discovered the functions of myoblasts are severely affected by the absence of dystrophin, and these cells are critically important for normal muscle growth but also regeneration.
Because these myogenic cells malfunction, damaged muscle cant be repaired effectively. And any repaired myofiber will eventually need to be replaced, which will not happen without myogenic cells, so it becomes a vicious circle.
Last year, the team , from its initial trigger and first manifestation. They found evidence of abnormalities even before birth in the embryo. Most boys with DMD are diagnosed between two and five years old by which time the damage to their bodies is already significant. This delay in identifying the condition may be preventing therapeutic interventions that could help slow, if not stop, disease progression.
At the moment were targeting the late stage of this disease by treating patients in their teens when muscle degeneration has already taken its toll, added Professor Gorecki.
Instead, if we try to correct cells that are at the beginning of the pathological process we might be able to delay muscle degeneration and extend a patients lifespan. We can do this by identifying and treating DMD newborns and targeting myogenic cells.
The paper says new technologies could be the key to producing effective therapies for this devastating disease.